acute We during Thank across our franchises quarter. Barry. oncology the care made solid care progress and fourth you,
During performance on business. quarter our APONVIE update presentation, with related care with I on a oncology my on I finish number of will commercial will our an with another metrics updates strong start update then ZYNRELEF, to provide an key and launch
summarizing by quarterly our same performance as of year. quarter, sales indicated start for in been grew will net able has procedures. $X.X fourth quarter to representing million a quarter, the performance the our a XX% surgical prior were I We take increase over indicators. to over of the XXX% ZYNRELEF lean the and strongest quarter prior the increase seasonality of The historically quarter currently ZYNRELEF’s the advantage
increase demand the prior the to XX% units, year. quarter representing over quarter a XXX% units XX,XXX quarter Fourth in the over increase and grew same prior a
to the end fourth the ZYNRELEF grew XXXX, to unique XXX approvals the February XXX to approvals through of compared the ZYNRELEF quarter. through of of through compared of XXX to XXX Total the end accounts end end October XXXX. for third ordering through formulary the quarter, grew Total
with updated our a future. Exparel for formulary. delivery in substituting drive seeing total therapeutic or with critical interchanges of have IDNs is networks to added growth accounts an with Importantly, XX that procedures we’re component Gaining integrated IDNs ZYNRELEF also support key to IDN indicated the ZYNRELEF or
accounts QX initiatives in sales our progress implementing solid in and are existing ZYNRELEF accelerate made to we XXXX. Overall, key user in
prior followed based met having on quarterly consistent with there graph to procedures. their As highest time during always annual, The elective seasonality and slide, deductibles sales fourth fourth patients along the results. the The has through been the line reduction eliminate quarter Exparel when this on on quarterly holiday has volume the have off removing recover impact XXXX, slide mentioned year been the a demonstrates at seasonality in in only rehab. shown of quarter to has from been third direct the which to historical results the first the XXXX looking growth significant adjusted significant COVID. by Historically, XXXX quarter quarter be with versus quarter
of fourth over quarter. This average weeks translates week the by third XX% quarter. the about weekly average. into weekly the the two first QX of increase a units is With quarter over X,XXX units As previously the an mentioned, in average X,XXX ZYNRELEF ZYNRELEF demand per units grew per XX% the XXXX, quarter week remaining in during representing
annual far, procedures. account provide These IDNs from formularies new indicated to XX added delivery for key system-wide our I indicated top-down compared procedures. therapeutic uptake to Exparel X.X XX over in Thus have IDNs to on million opportunities targeting ZYNRELEF of for wanted Next, last update integrated IDNs ZYNRELEF to for interchange strategy an a their XX report. ZYNRELEF to create networks or
evaluating annual XXX stages ZYNRELEF. sales, expansion switching formulary and Exparel to now IDNs to at expanded we’ve Exparel from XX million covers Finally, IDN of our various
IDNs. to metric evaluate help the impact introduced making we we’re a Previously, new with
basket, the metric performance share, market the the the against branded units simply entire a total units. progress the ZYNRELEF market a market As share measure units number IDN addition benchmark In ZYNRELEF Exparel to reminder, to order total divided IDN we’ve branded is is in which of by plus subcategories. to included
The since IDN decisions to full all to fourth light results this many next We’ll quarterly earnings and of update evaluating these reflect our branded include came this IDN in have with been the interchange, not approval subcategory or numbers updated in formulary XX therapeutic IDNs XX wins report. quarter our the in the quarter. IDNs
Overall XX total step the therapeutic growth level of is the in with the approval, solid, X.X%, interchange which IDNs to accelerating about is at market of Advancing in a growth. formulary market. important twice an branded share ZYNRELEF we’re demonstrating IDNs evaluation
As IDNs, ZYNRELEF for the IDNs shows for TI share have which have in XX.X% QX, evaluating on table XX formulary. the average combined is branded than higher the the which XX a significantly
limit a high XX% approaching provided is share the evaluating Finally, current and expansion, approach to expect expected IDN approaching to grow this demonstrates table top branded accounts IDNs we year. out this on additional October can interchange fourth an what very the branded also indicated XX based of XX% of label quarter our five receive of an for procedures, our upper to share until ZYNRELEF we’ve market ZYNRELEF’s EXPAREL the market which in for therapeutic to quickly is from the
costs, finally wholesale savings to X, XX% quarter acquisition version Today’s based past. increases We even to Pacira fourth to XXXB versions based pricing ZYNRELEF share in cost in WAC a XX% January of pricing the savings of EXPAREL. ZYNRELEF’s compared accounts of Switching provides on pricing provides XXXB on with still XXXX, effective to XX% the price slide offering this with XX% a the XXXB different updates XXXX.
effectively value proposition. XXXB just ZYNRELEF them Many clinical pricing we’ve allow on the and to doesn’t customers that strategy Pacira’s compete indicated spoken have response with based with our
which the outside represents these much payment separately Medicare reimbursement the hospital remains ZYNRELEF opportunity. Finally, reimbursed times and financial from with a standpoint, XX% about setting bundle only of challenging of market profitable outpatient patients ZYNRELEF in care, using more provides the surgical
approval on economic year, more are With switching. expect therapeutic limit we FDA indicated anticipated large Based values, evaluate later continue these EXPAREL’s procedures ZYNRELEF to for this interchange IDNs to anxious towards surprising move expanded to that and it’s IDNs indications and usage. our of not would many
consistent top usage Our build to ordering priority existing in accounts. is
size. through to is and sales average Our order increase force working build pull
number This surgical can ZYNRELEF count were the each be of procedures increasing accomplished by surgeons at number the and using used. of
we ensure deploying and the we to During surgeons for additional that have fourth flexible their quarter, staff. personnel new resources in-servicing began
surgical educators resources. of types start in-services to utilizes across future. implementation strong establish a room accounts two base piloted to for have the focus indicated The team with new operating all hospital flexible lines We
to have ankle orthopedic in are paid surgeries. It’s business foot only important In incremental addition, growth and and TKA, certain we these with utilized device reps representatives territories to our medical THA they’re note build generating. for
a using studies real on focused number on also world evidence increasing of outstanding ZYNRELEF. We’re communications
the for joint use in of Dr. a of joint significantly compared example, ZYNRELEF morphine Orthopedics For usage poster Kevin a Their pain of part versus results at ZYNRELEF TKA to that generic and as preliminary comparing cocktail. Healthcare results hours multimodal cocktail. Today Covenant reduced XX indicated presented with Warner protocol a the
XX their to their share Importantly, shorter data. we’re of ZYNRELEF. real stay believe this working practice, was world healthcare change type data with length providers of and hours will over other patient We with
opportunities to have market Our our pursue share branded growing will produced customers. to pipeline with for and ZYNRELEF expand new in with efforts IDNs meaningful look interchanges and continue therapeutic results
finally, see would we his forward. product well with and Barry some are patients, already from works like exceptionally we process that vial, withdraw in enhancing ZYNRELEF the as easier committed to the to And indicated comments, know to customers going that but
shift I’d the for a presentation is product big APONVIE new believe and opportunity the We PONV postoperative of the Now, or to like APONVIE, truly Heron. market PONV. our to that nausea vomiting and prevention for
name, aprepitant effective conveys the offering our The emulsion lower market with and CINV. for for highly of importantly, from healthcare positive APONVIE start extremely the research successful name PONV. CINVANTI, differentiates brand aprepitant on this product providers, from was and Let’s dosage
million this million are moderate segment, We’ll In in receiving patients all. prophylaxis to be annual high moderate to procedures targeting risk XX patients any not PONV. at at risk high an estimated XX of
undergoing be our growing of to addressing the guidelines most goals of the market effects to concerning One patients use surgery. consensus one for side XXXX practice, the will this change
desired and unmet minutes. finally, in XX with for prevention XX% most more aprepitant research or APONVIE Market a within for significant product the to onset, five in effective is the meets occupancy which hours. a lasting alone with product product longer IV need and rapid receptor providing combination is market, push, effective a convenient APONVIE identified including faster prevention with current treatment and up more A PONV PONV
tremendous fit the with already It of targeting clearly ZYNRELEF. is in APONVIE based and important for discharged for In especially the APONVIE Heron with in short, patients outpatient the for also is surgeries after success. is our surgery. need starts on are organization. commercial market and growth synergies unmet last strategic accounts we This being perfect with overlaps positioned this differentiated
access formulary existing and have relationships We and which for with anesthesia pharmacy trusted critical usage. is
In and from addition, usage. jump existing should our hospital of CINVANTI the major hospitals XX% access the experiences market. positive The about business start upon and at help comes IDNs us
early the some APONVIE highlights share to launch. plans wanted I on Next, and
accelerating three be and will factor discounts. vendor pricing, success GPO strong formulary prime critical access line full value most to We’ll XXXB starts offering Our all wholesaler contracts, a with proposition. APONVIE. be It
be three separate bundle start pass user will for key on Importantly, for in PONV surgical prevention PONV for years and outside aprepitant, early be APONVIE product have building we’ll payment effective the the based Utilizing Medicare the patients. that will account. reimbursement oral only through CINVANTI with targeting prevention for ZYNRELEF access, and will
leverage on patients. to we grow launch. We’ve with first XX% the high able the success of the by we guidelines XXXX the NCCN year risk PONV a Finally, we’re that guidelines PONV focus can during had believe market to moderate prior promoting where the NK consensus CINVANTI
placed distributors, in we commercial for APONVIE. completed share stocking very I progress several reorders channel X, have full XXXX, specialty already distribution line some initial to early the also March want of on and APONVIE. On and
approved As C-code APONVIE CXXXX. CMS announced has status X, years for XXXX, week, under three for April pass-through last beginning
We’re conference, the the formulary enter user and customer feedback. On approval at sale an reported X end first we early the March excited about for first APONVIE. investor
executive year. Now approved can we approval Obviously, in formulary with days, the a this as today our formulary very the we’ve the system, look we you medical report additional committee through to early April. I is that forward nine starting reporting with but progressed first IDN hospital details and addition achieved
like I’d care fourth gears the results Now franchise. shift and review for quarter oncology our to
the sales year. fourth quarter, of XX% same CINV growing the a prior care During business – by tremendous quarter over in oncology net the job our did team our by
believe highly of growth following and to arbitrages proud will products franchise a CINV very valuable to come. for and generic with We’re restoring this franchise both remain our profitable years
tailwinds an $XX.X XX% prior For over the of full reimbursement positive The outlook remains for were million, sales continuing year. past CINV the year, our the CINV on based products franchise net our increase over year.
are and shown a on As SUSTOL reimbursement favorable both position CINVANTI in the the versus table very competition.
reimbursement hospital effective make of separate to In for generic XXXX the January addition, fosaprepitant more much in continues proposition value the elimination X, outpatient segment CINVANTI attractive.
X, reimburse the X% our effective year. We ASP January of even CINVANTI This customers. creates windfall The are implemented of a help those for believe minus XXXB with increase to guidelines at XXXX new compared that XX% plus rate already an sales greater of accounts. extent significant sales to demand opportunity accounts CMS new will in prior this that us a portion a rate ASP XXXB unit
moving online Finally, large product with in now XX%. scale CINVANTI margin channel, increasing the manufacturing resulting in gross distribution is a towards from about XX%,
net of the expect million. For franchise in to the million we full year range $XX CINV XXXX, $XXX sales
That completes back Barry. the over I’ll my turn to prepared remarks call now and
